-
公开(公告)号：US20200009050A1
公开(公告)日：2020-01-09
申请号：US16554765
申请日：2019-08-29
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K31/704 , A61K9/00 , A61K9/14 , A61K9/51
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
-
公开(公告)号：US20190314530A1
公开(公告)日：2019-10-17
申请号：US16423377
申请日：2019-05-28
申请人： NANOBIOTIX
发明人： LAURENCE POUL , LAURENT LEVY , CELINE BERJAUD , MATTHIEU GERMAIN , AGNÉS POTTIER
摘要： The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring, typically in the context of therapy, in particular in the context of oncology, to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticle aggregates, wherein: i) the density of each nanoparticle and of each nanoparticle aggregate is at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s−1 of the gel comprising nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C.
-
公开(公告)号：US10391058B2
公开(公告)日：2019-08-27
申请号：US15529101
申请日：2015-11-24
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K9/51 , A61K9/00 , A61K31/704
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.
-
公开(公告)号：US20170258720A1
公开(公告)日：2017-09-14
申请号：US15529097
申请日：2015-11-24
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K9/00 , C07D491/14 , A61K31/37 , A61K9/51
CPC分类号： A61K9/1271 , A61K9/0019 , A61K9/0053 , A61K9/51 , A61K9/513 , A61K31/37 , A61K45/06 , A61K2121/00 , C07D491/14 , A61K2300/00
摘要： The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.
-
公开(公告)号：US20160136303A1
公开(公告)日：2016-05-19
申请号：US14898763
申请日：2014-06-19
申请人： NANOBIOTIX
发明人： LAURENCE POUL , LAURENT LEVY , CELINE BERJAUD , MATTHIEU GERMAIN , AGNES POTTIER
摘要： The present invention relates to compositions and methods for use in medical diagnosis and patient's monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein i) the nanoparticle and/or nanoparticles of the aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s−1 of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using X-ray imaging equipment.
摘要翻译： 本发明涉及用于医学诊断和患者监测的组合物和方法。 更具体地涉及包含纳米颗粒和/或纳米颗粒聚集体的生物相容性凝胶，其中i）聚集体的纳米颗粒和/或纳米颗粒包含无机材料，其包含至少一种原子序数Z为至少25的金属元素， 所述纳米颗粒和所述纳米颗粒聚集体被生物相容性涂层覆盖; ii）纳米颗粒和/或纳米颗粒聚集体浓度为约0.5％（w / w）; 和iii）当在20℃和37℃之间测量时，包含纳米颗粒和/或纳米颗粒聚集体的凝胶在2s -1处的表观粘度为约0.1Pa·s至约1000Pa·s。 当使用X射线成像设备观察所述组织时，本发明通常允许至少40％的靶生物组织的描绘和可视化。
-
公开(公告)号：US20230211175A1
公开(公告)日：2023-07-06
申请号：US17927372
申请日：2021-05-25
申请人： NANOBIOTIX S.A.
发明人： ELSA BORGHI , LAURENT LEVY
CPC分类号： A61N5/10 , B82Y5/00 , A61K33/24 , A61P35/00 , A61K45/06 , A61N2005/1087 , A61N2005/1098
摘要： The present disclosure offers therapeutic solutions to cancer patients up to now considered as unable to undergo a standard-of-care treatment involving radiotherapy or at high risk to undergo a standard-of-care treatment involving radiotherapy. The disclosure relates to nanoparticles and/or aggregates of nanoparticles for use in the treatment of cancer in such a patient, wherein the nanoparticles and/or aggregates of nanoparticles preferably comprise more than 30% by weight of at least one chemical element having an atomic number (Z) between 20 and 83. The disclosed treatments involve a step of administering the nanoparticles and/or aggregates of nanoparticles to the patient, and a step of exposing the patient to a total dose of ionizing radiations that is equal to or less than 85% of the total dose delivered in the standard-of-care treatment. The present description also discloses new compositions comprising such nanoparticles and/or aggregates of nanoparticles as well as uses thereof.
-
公开(公告)号：US11497717B2
公开(公告)日：2022-11-15
申请号：US16955092
申请日：2018-12-18
申请人： NANOBIOTIX S.A.
发明人： Marie-Edith Meyre , Laurent Levy , Agnès Pottier
摘要： The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.
-
公开(公告)号：US11229705B2
公开(公告)日：2022-01-25
申请号：US16472216
申请日：2017-12-19
申请人： NANOBIOTIX
发明人： Agnès Pottier , Laurent Levy , Marie-Edith Meyre
摘要： The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
9.发明申请公开(公告)号：US20210283256A1
公开(公告)日：2021-09-16
申请号：US17331674
申请日：2021-05-27
申请人： NANOBIOTIX
发明人： ELSA BORGHI , LAURENT LEVY , AGNES POTTIER
摘要： The present application relates to activable inorganic nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cancerous cells, tissues or organs. It more particularly relates to nanoparticles which can generate a surprisingly efficient therapeutic effect, when concentrated inside the tumor and exposed to ionizing radiations. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
-
公开(公告)号：US10064962B2
公开(公告)日：2018-09-04
申请号：US14886326
申请日：2015-10-19
发明人： Agnés Pottier , Laurent Levy , Marie-Edith Meyre , Matthieu Germain , Cyril Lorenzato , Chrit Moonen , Pierre Smirnov
IPC分类号： A61K9/127 , A61K49/18 , A61K9/00 , A61K9/50 , A61K9/51 , A61K41/00 , A61K31/704 , G01N24/08 , G01R33/56
摘要： The invention pertains to a method of monitoring the membrane permeabilization of a liposome and the incidental release of a compound of interest. The method utilizes liposomes comprising a thermosensitive lipidic membrane encapsulating the product of interest and superparamagnetic nanoparticles having the electrostatic surface charge below −20 mV or above +20 mV when measured in an aqueous medium at physiological pH. In one embodiment, the method comprises the steps of: a) measuring relaxation time (T2*); b) heating the liposome at Tm or above Tm; c) measuring T2* after step b); d) obtaining the transverse relaxivity (r2*) values from the T2* values obtained from step a) and step c); and e) determining the ratio of r2* before and after the heating step b). A ratio above 1.5 indicates the liposome membrane permeabilization and the incidental release of the product of interest.
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.018 秒)
